Explore the latest news and publications from Latigo Biotherapeutics
Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain
October 16, 2024
Potential best-in-class non-opioid Nav1.8 inhibitor, LTG-305 aims to provide safer treatment for chronic pain by…
Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors
September 9, 2024
Former William Blair partner and group head, Lugo has facilitated raising more than $6 billion…
Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Singla, M.D., Chief Medical Officer
August 19, 2024
Positive Phase 1 results for LTG-001, Latigo’s potential best-in-class non-opioid Nav1.8 inhibitor, demonstrated it to…
Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth
July 22, 2024
Farzan brings more than two decades’ leadership experience with a strong track record in fundraising…
Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action
February 23, 2024
Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders.
Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines
February 14, 2024
Potential best-in-class lead program targets Nav1.8, a validated human target for pain.